1. De-Ren S. Ten-year follow-up of esophageal cancer treated by radical radiation therapy : analysis of 869 patients. Int J Radiat Oncol Biol Phys 1989;16:329–34. doi:10.1016/0360-3016(89)90324-6 2. Newaishy GA, Read GA, Duncan W, Kerr GR. Results of radical radiotherapy of squamous cell carcinoma of the esophagus. Clin Radiol 1982;33:347–52. doi:10.1016/S0009-9260(82)80288-2 3. Okawa T, Kita M, Tanaka M, Ikeda M. Results of radiotherapy for inoperable locally advanced esophageal cancer. Int J Radiat Oncol Biol Phys 1989;17:49–54. doi:10.1016/0360-3016(89)90369-6 4. Smyth E, Schoder H, Strong VE, Capanu M, Kelsen DP, Coit DG, et al. A prospective evaluation of the utility of 2-deoxy-2-18F Fluoro-D-Glucose Positron Emission Tomography and computed tomography in staging locally advanced gastric cancer. Cancer 2012;118:5481–8. doi: 10.1002/cncr.27550 5. Kozak KR, Moody JS. The survival impact of the Intergroup 0116 trial on patients with gastric cancer. Int J Radiat Oncol Biol Phys 2008;72:517–21. doi:10.1016/j. ijrobp.2007.12.029 6. Shi X, Yao W, Liu T. Late course accelerated fractionation in radiotherapy of esophageal carcinoma. Radiother Oncol 1999;51:21–6. doi:10.1016/S0167- 8140(99)00017-1
7. Moni J, Armstrong JG, Minsky BD, Bains MS, Harrison LB. High dose rate intraluminal brachytherapy for carcinoma of the esophagus. Dis Esoph 1996;9:123–7.
8. Calais G, Dorval E, Louisot P, Bourlie P, Klein V, Chapet S, et al. Radiotherapy with high dose rate brachytherapy boost and concomitant chemotherapy for stages IIB and III esophageal carcinoma: results of a pilot study. Int J Radiat Oncol Biol Phys 1997;38:769–75. doi:10.1016/ S0360-3016(97)00077-1
9. Schraube P, Fritz P, Wannenmacher MF. Combined endoluminal and external irradiation of inoperable
Advances in the management of esophageal cancer
Year 2015,
Special Issue :1 Oncology, 3 - 10, 30.09.2015
The management of clinical stage III and IVa esophageal cancer has evolved in the past 2 decades. Based on the Cross trial, neoadjuvant chemoradiation, followed by surgical resection has become standard. For medically inoperable, definitive chemoradiation is most commonly used. The standard radiation dose is 50.4 Gy although trials of doseescalation are ongoing. At the current time, there are no definitive biomarkers to predict response.
1. De-Ren S. Ten-year follow-up of esophageal cancer treated by radical radiation therapy : analysis of 869 patients. Int J Radiat Oncol Biol Phys 1989;16:329–34. doi:10.1016/0360-3016(89)90324-6 2. Newaishy GA, Read GA, Duncan W, Kerr GR. Results of radical radiotherapy of squamous cell carcinoma of the esophagus. Clin Radiol 1982;33:347–52. doi:10.1016/S0009-9260(82)80288-2 3. Okawa T, Kita M, Tanaka M, Ikeda M. Results of radiotherapy for inoperable locally advanced esophageal cancer. Int J Radiat Oncol Biol Phys 1989;17:49–54. doi:10.1016/0360-3016(89)90369-6 4. Smyth E, Schoder H, Strong VE, Capanu M, Kelsen DP, Coit DG, et al. A prospective evaluation of the utility of 2-deoxy-2-18F Fluoro-D-Glucose Positron Emission Tomography and computed tomography in staging locally advanced gastric cancer. Cancer 2012;118:5481–8. doi: 10.1002/cncr.27550 5. Kozak KR, Moody JS. The survival impact of the Intergroup 0116 trial on patients with gastric cancer. Int J Radiat Oncol Biol Phys 2008;72:517–21. doi:10.1016/j. ijrobp.2007.12.029 6. Shi X, Yao W, Liu T. Late course accelerated fractionation in radiotherapy of esophageal carcinoma. Radiother Oncol 1999;51:21–6. doi:10.1016/S0167- 8140(99)00017-1
7. Moni J, Armstrong JG, Minsky BD, Bains MS, Harrison LB. High dose rate intraluminal brachytherapy for carcinoma of the esophagus. Dis Esoph 1996;9:123–7.
8. Calais G, Dorval E, Louisot P, Bourlie P, Klein V, Chapet S, et al. Radiotherapy with high dose rate brachytherapy boost and concomitant chemotherapy for stages IIB and III esophageal carcinoma: results of a pilot study. Int J Radiat Oncol Biol Phys 1997;38:769–75. doi:10.1016/ S0360-3016(97)00077-1
9. Schraube P, Fritz P, Wannenmacher MF. Combined endoluminal and external irradiation of inoperable
Mınsky, B. D. (2015). Advances in the management of esophageal cancer. Marmara Medical Journal, 28(1), 3-10. https://doi.org/10.5472/mmj.10059
AMA
Mınsky BD. Advances in the management of esophageal cancer. Marmara Med J. September 2015;28(1):3-10. doi:10.5472/mmj.10059
Chicago
Mınsky, Bruce D. “Advances in the Management of Esophageal Cancer”. Marmara Medical Journal 28, no. 1 (September 2015): 3-10. https://doi.org/10.5472/mmj.10059.
EndNote
Mınsky BD (September 1, 2015) Advances in the management of esophageal cancer. Marmara Medical Journal 28 1 3–10.
IEEE
B. D. Mınsky, “Advances in the management of esophageal cancer”, Marmara Med J, vol. 28, no. 1, pp. 3–10, 2015, doi: 10.5472/mmj.10059.
ISNAD
Mınsky, Bruce D. “Advances in the Management of Esophageal Cancer”. Marmara Medical Journal 28/1 (September 2015), 3-10. https://doi.org/10.5472/mmj.10059.
JAMA
Mınsky BD. Advances in the management of esophageal cancer. Marmara Med J. 2015;28:3–10.
MLA
Mınsky, Bruce D. “Advances in the Management of Esophageal Cancer”. Marmara Medical Journal, vol. 28, no. 1, 2015, pp. 3-10, doi:10.5472/mmj.10059.
Vancouver
Mınsky BD. Advances in the management of esophageal cancer. Marmara Med J. 2015;28(1):3-10.